Linxiaoxiao Ding
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Comparison of Clinicopathological Features and Survival Between Distant Lymph Node Metastasis and Distant Micrometastasis in Breast Cancer.
Journal: Clinical breast cancer
Published: April 07, 2026
Clinical outcomes and genomic landscape of anti-HER2 antibody-drug conjugates in HER2-positive and HER2-low metastatic breast cancer.
Journal: Therapeutic advances in medical oncology
Published: March 28, 2026
Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial.
Journal: Signal transduction and targeted therapy
Published: September 04, 2025
Prognostic Value of Distant Micrometastasis in Breast Cancer: A Population-Based Propensity Score-Matched Study.
Journal: International journal of women's health
Published: August 24, 2025
Ophthalmotoxicity induced by antibody-drug conjugates: a pharmacovigilance study of the FDA adverse event reporting system (FAERS).
Journal: Expert opinion on drug safety
Published: April 09, 2025
Causality between telomere length and breast diseases: a two-sample bidirectional Mendelian randomization study.
Journal: Annals of medicine and surgery (2012)
Published: March 17, 2025
Excellent efficacy of trastuzumab deruxtecan in a patient with HER2-positive advanced breast cancer complicated by pulmonary lymphangitic carcinomatosis: a case report and literature review.
Journal: Frontiers in pharmacology
Published: February 10, 2025
Combined pyrotinib and fulvestrant for hormone receptor-positive and HER2-positive metastatic breast cancer: A multicenter, single-arm, phase II trial.
Journal: MedComm
Published: September 08, 2024
Ductal lavage followed by observation versus oral corticosteroids in idiopathic granulomatous mastitis: A randomized trial.
Journal: Nature communications
Published: January 09, 2024
TP53-specific mutations serve as a potential biomarker for homologous recombination deficiency in breast cancer: a clinical next-generation sequencing study.
Journal: Precision clinical medicine
Published: January 08, 2024
Sequential neoadjuvant chemotherapy using pegylated liposomal doxorubicin and cyclophosphamide followed by taxanes with complete trastuzumab and pertuzumab treatment for HER2-positive breast cancer: A phase II single-arm study.
Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
Published: November 10, 2023
Assessing real-world safety concerns of Sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system.
Journal: Frontiers in oncology
Published: August 13, 2023
Last Updated: 09/26/2026